Special Issue "Wnt Signaling in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 March 2016) | Viewed by 146579
Interests: breast cancer; stem cells; mammary gland development; Wnt-signal transduction
The Wnt pathway is crucial for development and tissue homeostasis in all multicellular animals. It is characterized by a large genetic complexity (the mammalian genome encodes 19 Wnt proteins) and dynamic spatiotemporal activities. Ever since its discovery, Wnt signaling has also been closely associated with tumor initiation and progression. This ranges from the identification of the APC tumor suppressor gene as the quintessential gatekeeper in colorectal cancer formation, to more subtle changes in Wnt-pathway activity in breast and other cancers that are only beginning to be recognized. Following the realization that Wnt signaling controls stem cell maintenance in multiple tissues, it has also become a prime candidate for driving cancer stem cell self-renewal in different tumor types.
While much of the focus has so far been on Wnt/beta-catenin signaling (the so-called ‘canonical’ Wnt pathway), alternative Wnt-signaling responses also play an important role. In melanoma, for instance, cells may change from a Wnt/beta-catenin to a Wnt5a/Ror2 signaling state, thereby simultaneously switching from a more proliferative to a more invasive phenotype. As we develop a better understanding of the molecular complexity underlying the different intracellular responses, we can ultimately hope to devise specific interventions for each of these different signaling mechanisms.
Unfortunately, drug development efforts directly aimed at blocking Wnt signaling at the level of the best-known downstream effector, beta-catenin, have been largely unsuccessful. More recently, however, Wnt-secretion inhibitors as well as drugs that block the interaction between Wnt proteins and their receptors have entered clinical trials. This Special Issue will highlight the role of Wnt signaling in cancer in all its diversity, covering both basic and more (pre)clinical aspects that advance our understanding of targeting this complex pathway in human tumors.
Dr. Renée van Amerongen
Prof. Dr. Walter Birchmeier
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Wnt signaling
- Targeted therapy
- Cancer stem cells
- Ror 2